Hartley, A. E., Sanderson, E. C. M., Paternoster, L., Teumer, A., Kaplan, R. C., Tobias, J. H., & Gregson, C. L. (2020). Mendelian randomization provides evidence for a causal effect of higher serum IGF-1 concentration on risk of hip and knee osteoarthritis. *Rheumatology*, [keaa597].
https://doi.org/10.1093/rheumatology/keaa597

Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1093/rheumatology/keaa597

Link to publication record in Explore Bristol Research
PDF-document

---

This is the final published version of the article (version of record). It first appeared online via Oxford University Press at https://doi.org/10.1093/rheumatology/keaa597. Please refer to any applicable terms of use of the publisher.

**University of Bristol - Explore Bristol Research**

**General rights**

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
Mendelian randomization provides evidence for a causal effect of higher serum IGF-1 concentration on risk of hip and knee osteoarthritis

April Hartley 1,2, Eleanor Sanderson 1, Lavinia Paternoster 1, Alexander Teumer 3, Robert C. Kaplan 4, Jon H. Tobias 1,2 and Celia L. Gregson 2

Abstract

Objectives. How insulin-like growth factor-1 (IGF-1) is related to OA is not well understood. We determined relationships between IGF-1 and hospital-diagnosed hand, hip and knee OA in UK Biobank, using Mendelian randomization (MR) to determine causality.

Methods. Serum IGF-1 was assessed by chemiluminescent immunoassay. OA was determined using Hospital Episode Statistics. One-sample MR (1SMR) was performed using two-stage least-squares regression, with an unweighted IGF-1 genetic risk score as an instrument. Multivariable MR included BMI as an additional exposure (instrumented by BMI genetic risk score). MR analyses were adjusted for sex, genotyping chip and principal components. We then performed two-sample MR (2SMR) using summary statistics from Cohorts for Heart and Aging Research in Genetic Epidemiology (CHARGE) (IGF-1, N = 30,884) and the recent genome-wide association study meta-analysis (N = 455,221) of UK Biobank and Arthritis Research UK OA Genetics (arcOGEN).

Results. A total of 332,092 adults in UK Biobank had complete data. Their mean (s.d.) age was 56.5 (8.0) years and 54% were female. IGF-1 was observationally related to a reduced odds of hand OA [odds ratio per doubling = 0.87 (95% CI 0.82, 0.93)], and an increased odds of hip OA [1.04 (1.01, 1.07)], but was unrelated to knee OA [0.99 (0.96, 1.01)]. Using 1SMR, we found strong evidence for an increased risk of hip [odds ratio per s.d. increase = 1.57 (1.21, 2.01)] and knee [1.30 (1.07, 1.58)] OA with increasing IGF-1 concentration. By contrast, we found no evidence for a causal effect of IGF-1 concentration on hand OA [0.98 (0.57, 1.70)]. Results were consistent when estimated using 2SMR and in multivariable MR analyses accounting for BMI.

Conclusion. We have found evidence that increased serum IGF-1 is causally related to higher risk of hip and knee OA.

Key words: OA, UK Biobank, insulin-like growth factor-1, Mendelian randomization, BMI

Rheumatology key messages

- Genetically determined serum insulin-like growth factor-1 is related to an increased risk of hip and knee OA.
- A high genetic risk for increased insulin-like growth factor-1 and BMI confers the highest risk for hip OA.
- Overall, results suggest a causal role of serum insulin-like growth factor-1 in hip and knee OA.

Introduction

OA is highly prevalent, with an estimated 3.8% of the worldwide population affected by knee and 0.9% by hip OA [1]. Currently there are no disease-modifying drugs available; therapy consists of pain management and, when severe, joint replacement, with an estimated cost greater than £850 million in the UK for primary knee and hip replacement [2].
Insulin-like growth factor-1 (IGF-1) is a hormone regulating skeletal growth and development [3]. Most circulating IGF-1 is produced by the liver in response to growth hormone stimulation [3], whilst some is produced by specific tissues, e.g. chondrocytes [3, 4]. *In vitro* studies of animal cartilage suggest that IGF-1 can stimulate proteoglycan synthesis [5], upregulate type 2 collagen and downregulate MMP-13 expression [6], all of which imply that IGF-1 may be protective against cartilage degeneration (and hence OA). Epidemiological evidence supporting an IGF-1–OA association has been inconclusive [7], with the largest cross-sectional study (*N* = 761) identifying a positive association between IGF-1 concentration and bilateral knee OA [8]. A positive association between IGF-1 and OA risk is further supported by findings from individuals with acromegaly (a disorder of excess growth hormone production), who have increased OA risk [7]. Conversely, polymorphisms in the IGF-1 promoter region, associated with lower IGF-1 levels, have been linked to higher OA prevalence [9, 10]. BMI is a strong risk factor for OA [11] and is inversely related to IGF-1 [12]; BMI may therefore mediate any inverse association between IGF-1 and OA.

Mendelian randomization (MR) enables causal inference in epidemiology. MR uses genetic variants, robustly associated with an exposure, as an instrument for the exposure, to determine the causal relationship with an outcome [13]. As genetic variants are randomly assigned at conception and cannot be changed, the genetic instrument(s) is generally independent of confounders of the exposure–outcome relationship and unaffected by reverse causality [13]. Frequently, the instrument(s) may be related to the outcome via a causal pathway not mediated by the exposure (i.e. horizontal pleiotropy), violating a key assumption of MR [13]. Hence, multivariable MR (MVMR) methods have been developed to estimate the direct causal effect of the exposure on the outcome when the instrument(s) may affect the outcome through another related exposure, provided the related exposure is included in the model, along with valid instruments for each exposure [14].

We aimed to utilize the large-scale availability of data for serum IGF-1 in the UK Biobank population to firstly determine the observational associations between IGF-1 and hospital-diagnosed OA at the hand, hip and knee, and then to use MR to determine the causal effect of circulating IGF-1 on OA at each joint. After this, we aimed to use MVMR to determine whether any observed causal effects are independent of BMI.

**Methods**

**Observational analysis**

**UK Biobank population**

UK Biobank is a UK-wide population of ~500 000 people, aged 38–73 years, recruited during 2006–10 [15]. Participants provided a range of information (e.g. demographics, health status) via questionnaires and interviews; anthropometric measures and blood samples were collected (data available at: www.ukbiobank.ac.uk). A detailed description of the study design, participants and quality control (QC) methods is published elsewhere [15]. UK Biobank received ethical approval from the Research Ethics Committee (REC reference 11/NW/0382).

**Measurement of serum IGF-1**

Serum IGF-1 was measured at baseline using the Liaison XL chemiluminescent immunoasay, Diasorin Ltd (Dartford, UK) (data downloaded April 2019). Average within-laboratory coefficients of variation were 6.0% for low, 5.3% for medium and 6.2% for high concentrations [16]. QC procedures have been published [17].

**Determination of hospital-diagnosed OA**

Hand, hip and knee OA were determined from Hospital Episode Statistics [18] using the International Statistical Classification of Diseases and Related Health Problems (ICD) 9/10 codes previously reported for hand [19], hip and knee [20] OA (data downloaded January 2019). Inclusion (cases) and exclusion (controls) codes (to exclude controls with OA in other joints and inflammatory polyarthropathies) are listed in supplementary Table S1A and B, available at *Rheumatology* online, respectively.

**Covariates**

BMI was determined from measured height and weight at the assessment clinic [weight (kg)/height (m)²]. Ethnic background (Supplementary Methods, available at *Rheumatology* online) and oestrogen replacement therapy (ERT) use were ascertained by touchscreen questionnaire.

**Statistical analysis**

Positively skewed serum IGF-1 concentrations were log-transformed, and associations with binary OA outcomes determined using multivariable logistic regression. Analyses were performed in four stages: (i) unadjusted; (ii) adjusting for age and sex; (iii) additionally adjusting for ethnicity and ERT use; and (iv) additional adjustment for BMI. Coefficients were transformed by ln(2) to generate an odds ratio (OR) per doubling in IGF-1 concentration. Results are presented as OR per s.d. increase in IGF-1 in figures to allow comparison with MR estimates. Additional stratified analyses determined gender-specific associations. We did not correct our *P*-value threshold for multiple testing as our three outcomes are highly correlated. We performed sensitivity analyses excluding individuals with acromegaly (ICD10 code E220, ICD9 code 2530), endocrine-related arthropathy (M145, 7130) (N = 94) and individuals for whom serum IGF-1 was measured from an aliquot other than the first aliquot (N = 43 728), as sample dilution issues have been reported by UK Biobank and the dilution increases with increasing aliquot [17].
Mendelian randomization provides evidence for a causal effect of higher serum IGF-1 concentration

Causal inference using MR

Genotyping and imputation
Pre-imputation QC, phasing, imputation and QC filtering are described elsewhere [21, 22] and summarized in Supplementary Methods, available at Rheumatology online.

One-sample MR
Eight independent single nucleotide polymorphisms (SNPs) associated with IGF-1 at genome-wide significance, in the Cohorts for Heart and Aging Research in Genetic Epidemiology (CHARGE) meta-analysis, instrumented IGF-1 [23] (Table 1). Two of these SNPs were also associated with IGF-BP3 levels and one was identified from a bivariate analysis of IGF-1 and IGF-BP3. Analyses were performed using the individual SNPs (in the same analysis) and then an unweighted genetic risk score (GRS, generated by summing IGF-1-increasing allele dosage). One-sample (1SMR) analyses were adjusted for sex, genotyping chip and 10 principal components (PCs) (to account for population stratification, i.e. minor allele frequency variation due to ancestral differences). IGF-1 was standardized prior to analysis. Two-stage least-squares regression was performed using the ‘ivreg2’ package in Stata (StataCorp, College Station, Texas US) [24], which provides an estimate of the OR per S.D. increase in IGF-1 by first predicting values on the binary outcomes using logistic regression, and then regressing these predicted values on IGF-1, generating predicted values of IGF-1, and then regressing the instruments on IGF-1, generating predicted values for sex, genotyping chip and 10 PCs, using a linear mixed model within the software ‘BOLT’ [30], as described in the published protocol [31]. Steiger filtering was performed to identify SNPs explaining a greater proportion of variance in OA sub-phenotypes compared with IGF-1 [32]. No SNPs were identified for exclusion. Summary statistics are shown in supplementary Table S4, available at Rheumatology online. Causal effects were estimated using inverse-variance weighted regression, performed using the TwoSampleMR R package [33]. MR-Egger regression was also performed to estimate possible bias due to directional pleiotropy, i.e. to provide valid causal estimates even if one of the key assumptions of MR was invalidated (Fig. 1). MR-Egger does not constrain the intercept of the regression line between the SNP–exposure and the SNP–outcome estimates at 0, and thus produces a valid estimate if the correlation between the direct SNP–outcome effect (i.e.

### Table 1

| SNP   | EA  | IGF-1 | Hip OA | Knee OA |
|-------|-----|-------|--------|---------|
|       |     | Beta  | SE     | OR      | SE     | P      |
| rs1065656 | G   | 0.050 | 0.003 | 4 × 10^{-84} | 0.987 | 0.015 | 0.392 | 1.019 | 0.012 | 0.116 |
| rs2153960 | A   | 0.048 | 0.003 | 6 × 10^{-76} | 1.025 | 0.016 | 0.125 | 1.023 | 0.013 | 0.061 |
| rs509035  | A   | 0.054 | 0.003 | 5 × 10^{-102} | 0.998 | 0.015 | 0.897 | 1.011 | 0.012 | 0.342 |
| rs646776  | T   | -0.029 | 0.003 | 3 × 10^{-25} | 0.939 | 0.016 | 2 × 10^{-4} | 0.992 | 0.013 | 0.543 |
| rs700753  | G   | 0.113 | 0.002 | <1 × 10^{-300} | 0.982 | 0.015 | 0.234 | 0.984 | 0.011 | 0.155 |
| rs780093  | C   | 0.060 | 0.002 | 1 × 10^{-135} | 1.041 | 0.016 | 0.007 | 1.021 | 0.012 | 0.066 |
| rs934073  | G   | 0.035 | 0.003 | 4 × 10^{-43} | 1.011 | 0.016 | 0.471 | 1.000 | 0.012 | 0.988 |
| rs978458  | C   | -0.074 | 0.003 | 6 × 10^{-172} | 0.953 | 0.015 | 0.003 | 0.983 | 0.012 | 0.180 |
| IGF-1 GRS |     | 0.058 | 0.001 | <1 × 10^{-300} | 1.018 | 0.006 | 0.001 | 1.010 | 0.004 | 0.019 |

Adjusted for sex, genotyping chip and 10 principal components. Betas represent the per-effect allele increase in standardized IGF-1. *SNPs also associated with IGF-BP3 in the CHARGE meta-analysis [23]. IGF-1: insulin-like growth factor-1; EA: effect allele; NEA: alternative allele; EAF: effect allele frequency; OR: odds ratio; SE: standard error; GRS: genetic risk score; CHARGE: Cohorts for Heart and Aging Research in Genetic Epidemiology.

Two-sample MR
SNP-exposure summary data were extracted from the CHARGE meta-analysis [23]. The study employed a sample-size weighted Z-score based meta-analysis due to assay heterogeneity across cohorts, hence betas and SEs could not be generated [23]. Betas were estimated from P-values [from the IGF-1 genome-wide association study (GWAS)] using the method of Rietveld et al. [29]. Summary statistics are shown in supplementary Table S4, available at Rheumatology online. To provide estimates of the SNP–outcome association, summary statistics for the IGF-1 SNPs were extracted from the largest GWAS meta-analysis of hip and knee OA to date, from UK Biobank and Arthritis Research UK OA Genetics (arcOGEN; a population with severe OA) [20]. Estimates for hand OA were generated by our own GWAS of hospital-diagnosed hand OA in UK Biobank, adjusting for sex, genotyping chip and 10 PCs, using a linear mixed model within the software ‘BOLT’ [30], as described in the published protocol [31]. Steiger filtering was performed to identify SNPs explaining a greater proportion of variance in OA sub-phenotypes compared with IGF-1 [32]. No SNPs were identified for exclusion. Summary statistics are shown in supplementary Table S4, available at Rheumatology online. Causal effects were estimated using inverse-variance weighted regression, performed using the TwoSampleMR R package [33]. MR-Egger regression was also performed to estimate possible bias due to directional pleiotropy, i.e. to provide valid causal estimates even if one of the key assumptions of MR was invalidated (Fig. 1). MR-Egger does not constrain the intercept of the regression line between the SNP–exposure and the SNP–outcome estimates at 0, and thus produces a valid estimate if the correlation between the direct SNP–outcome effect (i.e.
For an MR effect estimate to be valid, the instrument(s) must satisfy three key assumptions [26]: IV1 [the instrument(s) must be robustly associated with the exposure]; IV2 [the instrument(s) must not be associated with any confounders of the exposure–outcome relationship]; and IV3 [the instrument(s) can only be associated with the outcome via the exposure and not via a different biological pathway independent of the exposure (i.e. horizontal pleiotropy)]. In one-sample analyses, IV1 was tested by calculating the F-statistic, which is a measure of instrument strength. A cutoff of ≥10 is used to determine sufficient instrument strength [13]. IV2 was tested by determining the association between the instruments and potential confounders of the exposure–outcome relationship. The Sargan statistic was used to detect evidence of potential pleiotropy; this statistic is a measure of variation in the outcome the instrument explains, independent of the exposure variable [14]. To limit potential horizontal pleiotropy, we repeated analyses excluding the SNPs also associated with IGF-BP3 at genome-wide significance (rs700753, rs646776, rs1065656) and using just the intronic IGF-1 SNP (rs978458) as the instrument. In 2S analyses, to satisfy IV1, we ensured that all instruments were robustly associated with the exposure by only including SNPs associated with the exposure at genome-wide significance. To address IV3, MR-Egger regression was performed to generate an estimate of horizontal pleiotropy. Cochran’s Q statistic was also calculated as a measure of potential pleiotropy. Weighted median regression was performed to determine the robustness of IVW estimates as weighted median estimates are valid even if up to 50% of the SNPs are not valid instruments [27]. To limit potential horizontal pleiotropy, we repeated analyses excluding the SNPs also associated with IGF-BP3. In MVMR, Sanderson-Windmeijer (S-W) conditional F-statistics were calculated for IGF-1 and BMI to determine conditional instrument strength [14]. MR: Mendelian randomization; SNP: single nucleotide polymorphism; IGF-1: insulin-like growth factor-1; IVW: inverse variance weighted.

Multivariable MR

We conducted one-sample MVMR to determine the BMI-independent causal effect of IGF-1 on OA. An unweighted BMI GRS was generated using the 63 independent SNPs (after linkage disequilibrium clumping with an $r^2$ threshold of 0.001) from the Genetic Investigation of Anthropometric Traits (GIANT) consortium GWAS of the European sex-combined population [35] (supplementary Table S5, available at Rheumatology online, details the SNPs and their association with BMI in UK Biobank). Analyses were performed as for 1SMR, with the inclusion of BMI and the BMI risk score in the two-stage least-squares regression model. MVMR was also performed with height (instead of BMI) as a covariate (supplementary Tables S2 and Table S6, available at Rheumatology online).

Factorial MR

Factorial MR was used to determine whether there is an effect of high IGF-1 on OA risk, over and above the effect of high BMI. The MR population was stratified by the median for IGF-1 GRS and for BMI GRS and then categorized as those: (i) below the median for IGF-1
GRS and BMI GRS; (ii) above/equal to the median for IGF-1 GRS and below the median for BMI GRS; (iii) below the median for IGF-1 GRS and above the median for BMI; and (iv) above the median for both IGF-1 and BMI GRS. Logistic regression analysed GRS category (exposure) and OA variables (outcomes) adjusting for sex, genotyping chip and 10 PCs.

Results

Participant characteristics

In total, 421,527 individuals had complete data for observational analyses, of whom 332,059 (79%) had genetic data and were included in MR analyses (supplementary Fig. S1, available at Rheumatology online, details sample derivation). The mean (s.d.) ages of the observational and MR populations were 56.4 (8.1) and 56.5 (8.0) years, respectively. In both populations 54% were female, mean BMI was 27.3 (4.7) kg/m² and IGF-1 concentration 21.5 (6) nmol/l (Table 2). In the observational population, 3.1% had hospital-diagnosed hip OA, 5.4% knee OA and 0.7% hand OA; respective proportions for the MR population were 3.2, 5.4 and 0.7%.

Evidence from the observational data

In unadjusted analyses, increasing IGF-1 concentration was associated with lower odds of hand, hip and knee OA (Table 3), with the strongest association seen for hand OA [OR per doubling = 0.61 (95% CI 0.57, 0.65), \(P = 1.5 \times 10^{-49}\)]. Adjustment for age and sex reduced the strength of all associations, although evidence remained for a protective association of IGF-1 on all three OA outcomes. Further adjustment for ethnicity and ERT use did not alter observed associations. However, IGF-1 was strongly inversely associated with BMI in the UK Biobank population, with an s.d. increase in IGF-1 associated with a 0.13 s.d. decrease in BMI. When BMI was added to the model, only evidence suggesting a protective association of IGF-1 on hand OA [OR = 1.04 (1.01, 1.07), \(P = 0.014\)] remained. Whilst the association between IGF-1 and knee OA was fully attenuated by BMI adjustment, some evidence emerged for an increased odds of hip OA [OR = 1.04 (1.01, 1.03), \(P = 2 \times 10^{-6}\)]. There was evidence of an interaction between log-transformed IGF-1 and BMI [OR for interaction term = 1.02 (1.01, 1.03), \(P = 2 \times 10^{-6}\)].

When BMI-adjusted analyses were stratified by sex, the association between IGF-1 and hip OA was only seen in females [OR_f = 1.07 (1.03, 1.12) vs OR_M = 1.00 (0.95, 1.05), supplementary Fig. S2, available at Rheumatology online]. The inverse association between IGF-1 and hand OA was seen with a similar magnitude in both sexes. Restricting analyses to 377,602 individuals whose IGF-1 was measured from their first aliquot did not alter conclusions drawn, nor did removing those with acromegaly, endocrine-related arthropathies or restricting to the MR population.

Evidence from MR analyses

In 1SMR analyses, using individual IGF-1-associated SNPs as instruments, we found evidence for an increased odds of hip OA with increasing IGF-1 concentration [OR per s.d. increase in IGF-1 = 1.20 (1.01, 1.43), \(P = 5.0 \times 10^{-7}\)].

Table 2

| Characteristic | Observational population (N = 421,527) | MR sub-population (N = 332,059) |
|---------------|--------------------------------------|---------------------------------|
|               | Mean ± s.d. | Mean ± s.d. | Mean ± s.d. |
| Age, years    | 56.4 ± 8.1  | 56.5 ± 8.0  | 56.9 ± 8.2  |
| Height, cm    | 168.6 ± 9.2 | 168.9 ± 9.2 | 169.1 ± 9.4 |
| Weight, kg    | 77.9 ± 15.8 | 78.0 ± 15.8 | 78.2 ± 15.9 |
| BMI, kg/m²    | 27.3 ± 4.7  | 27.3 ± 4.7  | 27.4 ± 4.7  |
| IGF-1, nmol/l | 21.3 ± 17.6 | 21.3 ± 17.6 | 21.3 ± 17.6 |
| N             | %          | N            | %          |
| Female        | 227,738 ± 54.0 | 178,699 ± 53.8 | 67,181 ± 37.8 |
| ERT use       | 84,341 ± 37.0 | 67,181 ± 37.8 | 67,181 ± 37.8 |
| Ethnicity     |            |              |            |
| White         | 401,844 ± 95.3 |              |              |
| Black/Black British | 6500 ± 1.5 |              |              |
| Asian/Asian British | 6489 ± 1.5 |              |              |
| Chinese       | 1335 ± 0.3  |              |              |
| Mixed         | 1619 ± 0.4  |              |              |
| Other         | 3740 ± 0.9  |              |              |
| Hospital-diagnosed OA |        |              |              |
| Hip           | 12,425 ± 3.1 |              | 9951 ± 3.2   |
| Knee          | 22,278 ± 5.4 |              | 17,338 ± 5.4 |
| Hand          | 2727 ± 0.7  |              | 2165 ± 0.7   |

*Values represent median and interquartile range. ERT: oestrogen replacement therapy; MR: Mendelian randomization.
Combining genotypes for the eight SNPs in a GRS strengthened the instrument (F-statistic: 3774 vs 563) and the evidence for a causal effect of IGF-1 on hip OA [OR = 1.35 (1.13, 1.63), \( P = 0.001 \), Fig. 2]. An effect of IGF-1 on knee OA was also observed when using the IGF-1 GRS instrument [OR = 1.19 (1.03, 1.37), \( P = 0.019 \)]. Although we found no evidence of a causal effect of IGF-1 on hand OA [OR = 0.88 (0.60, 1.31), \( P = 0.539 \)], these analyses were likely underpowered due to the rarity of hospital-diagnosed hand OA (supplementary Table S3, available at Rheumatology online). Evidence for a causal effect of IGF-1 on hip and knee OA was stronger when excluding the three SNPs also associated with IGF-BP3 levels [ORhip = 1.57 (1.21, 2.02), \( P = 0.001 \) and ORknee = 1.30 (1.07, 1.58), \( P = 0.008 \), supplementary Table S7, available at Rheumatology online]. The Sargan statistic was reduced from 30.5 (\( P < 0.001 \)) to 4.4 (\( P = 0.35 \)), suggesting that results were less biased by pleiotropy when excluding IGF-BP3 SNPs. Effects persisted when restricting to the

**FIG. 2** Comparison of observational and MR estimates of the effect of IGF-1 on hand, hip and knee OA

Points represent odds ratios for OA per standard deviation increase in IGF-1 concentration. Horizontal bars represent 95% CIs. Observational analyses adjusted for age, sex, ERT, ethnicity and BMI. MR analyses adjusted for sex, genotyping chip and 10 principal components. OR: odds ratio; 1SMR: one-sample Mendelian randomization; 2SMR: two-sample Mendelian randomization; MVMR: multivariable Mendelian randomization; MR: Mendelian randomization; IGF-1: insulin-like growth factor-1; ERT: oestrogen replacement therapy.

ORs are per doubling in IGF-1 concentration. IGF-1: insulin-like growth factor-1; OR: odds ratio; ERT: oestrogen replacement therapy.
single intronic IGF-1 SNP [OR\textsubscript{hip} = 1.93 (1.25, 2.97), \(P = 0.003\) and OR\textsubscript{knee} = 1.26 (0.90, 1.76), \(P = 0.179\)]. When stratifying by sex, stronger evidence for an effect of IGF-1 on hip OA was seen in females (supplementary Fig. S2, available at Rheumatology online), although analysis in males had lower power due to smaller sample size (supplementary Table S3, available at Rheumatology online). When checking the assumptions of 1SMR, we found evidence for an association between the IGF-1 GRS and both BMI and ERT use (supplementary Table S8, available at Rheumatology online), violating assumption IV2 (Fig. 1). Despite a strong inverse relationship between BMI and measured IGF-1, the association between the IGF-1 GRS and BMI was positive. We repeated 1SMR, adjusting for ERT use, which did not attenuate the association between IGF-1 and hip OA.

When determining the causal relationship using 2SMR, although CIs widened, effect sizes were similar (Fig. 2), with findings consistent with a positive effect of IGF-1 on hip OA [OR = 1.26 (0.99, 1.61), \(P = 0.065\)]. The MR-Egger estimate differed in direction of effect (supplementary Figs S3 and S4, available at Rheumatology online), suggesting horizontal pleiotropy may explain the observed association (Cochran’s Q = 19.6, \(P = 0.007\)). Further evidence for a potential pleiotropic effect was supported by two outlying SNPs (supplementary Fig. S4, available at Rheumatology online), rs646776 and rs700753; both were associated with IGF-BP3. When removing all three SNPs associated with IGF-BP3, the causal effect estimate for IGF-1 strengthened [OR = 1.49 (1.21, 1.83), \(P = 1 \times 10^{-4}\)] and was consistent in direction with the MR-Egger estimate [OR = 5.88 (0.70, 49.13), \(P = 0.200\), P for intercept = 0.292, supplementary Table S7, available at Rheumatology online]. Cochran’s Q was also reduced (Q\textsubscript{hip} = 4.4, \(P = 0.354\) and Q\textsubscript{knee} = 5.9, \(P = 0.206\)). We found no evidence of a causal effect of IGF-BP3 on hip or knee OA risk, but some evidence for a protective effect of IGF-BP3 on hand OA (supplementary Table S9, available at Rheumatology online). The effect of IGF-1 on hip OA was even stronger when restricting to the single intronic IGF1 SNP [OR = 1.92 (1.22, 3.03), \(P = 0.005\)].

We postulated that BMI could mediate the effect of IGF-1 on hip OA; therefore, we performed MVMR to determine the causal effect of IGF-1 on hospital-diagnosed OA, independent of BMI. We found evidence for a BMI-independent causal pathway between IGF-1 and hip OA [OR = 1.32 (1.09, 1.58), \(P = 0.004\), with weaker evidence for a causal effect on knee OA [OR = 1.14 (0.99, 1.31), \(P = 0.078\), Fig. 2]. Evidence for a causal effect of IGF-1 on both hip and knee OA was stronger after excluding the IGF-BP3 SNPs (supplementary Table S7, available at Rheumatology online). The effect sizes for the causal role of IGF-1 on hip and knee OA were unchanged when performing MVMR with height instead of BMI (supplementary Table S2, available at Rheumatology online). Like univariable MR, a stronger effect of IGF-1 on hip OA was seen in females than males (supplementary Fig. S2, available at Rheumatology online), although this could be due to the smaller sample size of the male population.

We next performed factorial MR to identify any additive effect of IGF-1 and BMI on OA. Those with a BMI and IGF-1 GRS above the median had the greatest odds of hip OA [OR = 1.12 (1.06, 1.18), \(P = 1 \times 10^{-4}\)] compared with those with scores below the median (Fig. 3), suggesting an additive effect of higher serum IGF-1 and higher BMI on hip OA risk. No difference in the odds of knee OA was apparent between those with a high BMI GRS and low IGF-1 GRS vs those with a high IGF-1 GRS and high BMI GRS (Fig. 3). Results were similar when stratified by sex (supplementary Fig. S5, available at Rheumatology online).

In summary, our observational analyses provide evidence for a protective effect of higher serum IGF-1 on hand OA but an increased odds of hip OA after adjustment for BMI. An increased odds of hip OA is consistent with the MR analyses, which provided evidence for a causal effect of IGF-1 on hip and knee OA. Observational and factorial MR analyses both provided evidence for an interaction between high serum IGF-1 and high BMI on hip OA risk.

Discussion
We have found evidence for a causal effect of higher circulating IGF-1 on the risk of hospital-diagnosed hip OA in a large population-based cohort of white European adults. This effect is independent of BMI. Both observational and MR analyses suggested that the effect of IGF-1 on hip OA is greater in those with a higher BMI, suggesting BMI modifies the effect of IGF-1 on hip OA. We detected evidence for a causal role of IGF-1 as a risk factor for knee OA, though this was weaker than that for hip OA. To the best of our knowledge, this is the first study to use MR to determine the causal relationships between IGF-1 and OA at the hand, hip or knee. Two prior studies have identified a positive relationship between a microsatellite polymorphism in the IGF-1 promoter and radiographic hip OA [9, 10]. However, this polymorphism was also related to lower serum IGF-1 concentrations in a subset of 50 individuals [36], but the authors could not conclude that the SNP was the causal variant, or in linkage disequilibrium with a variant causing OA [10].

The lack of observational evidence for an association between IGF-1 and knee OA is consistent with a previous case–control study (Framingham Osteoarthritis Study) of both incident and progressive radiographic knee OA [37], and a cross-sectional analysis in the Baltimore Longitudinal Study of Aging [38]. Lloyd et al. [8] identified a positive association between IGF-1 and radiographic knee OA in the Chingford population, but only for severe and bilateral knee OA. Our phenotype of hospital-diagnosed OA is likely to reflect more severe radiographic or more clinically apparent (i.e. painful) OA. We lacked data on whether cases had bilateral or unilateral disease, which may contribute to the inconsistency
in findings. Furthermore, Lloyd et al. [8] found weak evidence for increased serum IGF-1 in individuals with radiographic DIP joint OA, which contrasts with the protective association between IGF-1 and hand OA that we observed. Although the age-standardized prevalence of radiographic hand OA was 27% in the US Framingham population [39], UK hospital-diagnosis was much rarer, likely due to the lack of surgical management options for hand OA, meaning our MR analyses of hand OA were underpowered to confirm or refute the reported effect.

Consistent with a role of the IGF-1/IGF-BP axis on hip OA risk, a GWAS of hip OA identified two loci near IGF-BP3 [40] where SNPs were associated with a decreased odds of hip OA and decreased circulating IGF-BP3 (not IGF-1) [40]. In vivo functional studies suggest that IGF-BP3 overexpression in cartilage from patients with knee OA results in decreased aggrecan and increased MMP-13 expression, two markers of cartilage degradation [40]. The two OA-associated SNPs near IGF-BP3 were not instruments in our analyses, nor in linkage disequilibrium with any of the SNPs used in our instrument. Our two-sample MR analyses did not suggest a causal effect of circulating IGF-BP3 on hip OA risk.

The lack of consistency between our observational and MR results may reflect the difference in exposures; for observational analyses, the exposure was current measured IGF-1 levels whereas for MR analyses, the exposure was genetically predicted IGF-1 levels [41]. Different relationships of measured IGF-1 and the IGF-1 GRS with BMI may be explained by a negative feedback loop, whereby higher IGF-1 levels throughout the life-course lead to a higher body mass, which, over a sustained period of time, may reduce IGF-1 production by the liver [12]. However, the BMI GRS was not associated with current IGF-1 levels \( \beta = 3.12 \times 10^{-4} \) (95% CI –0.004, 0.004). We therefore hypothesize that higher IGF-1 throughout the life-course may drive the progression of OA, and our MVMR analyses suggest that this effect is not mediated by BMI. One potential pathway is via increased bone mineral density (BMD), a reported risk factor for hip OA [42]. IGF-1 contributes to skeletal development and increases BMD by promoting mesenchymal stem cell differentiation into osteoblasts [43]. However, adjustment for BMD did not attenuate our observational relationship between IGF-1 and hip OA (data not shown). An alternative explanation is that increased IGF-1 during development may lead to alterations in hip shape. IGF-1 is important for endochondral bone formation [44] and several genes linked to endochondral bone formation were identified in a recent GWAS meta-analysis of hip shape [45]. Variation in hip shape is associated with hip OA [46]. A cohort with IGF-1 and hip shape measured prior to OA onset (i.e. an adolescent cohort) is needed to better understand this relationship.

As we observed a stronger effect of IGF-1 on hip OA in females, we further hypothesized that IGF-1 levels could lower circulating oestrogen levels, leading to increased

---

**Fig. 3** Factorial MR analysis of the interaction between IGF-1 and BMI on hip and knee OA risk

Points represent the odds ratio for individuals in each BMI/IGF-1 GRS category compared with those with a BMI risk score below the median and an IGF-1 score below the median (reference category). Horizontal bars represent 95% CIs. Analyses adjusted for sex, genotyping chip and 10 principal components. MR: Mendelian randomization; IGF-1: insulin-like growth factor-1; GRS: genetic risk score.
A major strength of this analysis is the availability of extensive data for both IGF-1 concentrations and hospital-diagnosed OA for >400,000 individuals, making this the most well-powered study to determine the observational relationship between IGF-1 and OA, to date. Furthermore, we had genotype data available for >300,000 individuals, providing 80% power to detect a causal OR of >1.28. The availability of these genetic data enabled us to perform one-sample MVMR analysis to determine the true causal effect of IGF-1 on hip OA, independent of BMI. However, we acknowledge limitations within these analyses. Although we excluded controls with other diagnosed arthropathies, some may still have had undiagnosed OA, although this would likely bias results towards the null. Our sex-stratified and hand OA analyses had low power, meaning we are unable to draw robust conclusions. The effect sizes of the summary statistics for the SNP-IGF-1 associations, used for two-sample MR analyses, were approximated as an s.d. unit change in IGF-1 from the corresponding P-values, direction of association, sample size and allele frequency [29]. However, these effect estimates were not used for 1SMR, which generated consistent results. We chose not to generate our BMI instrument from the largest GWAS of BMI, as a large proportion of individuals included in this meta-analysis were from UK Biobank and we were concerned about overestimating causal effect estimates due to ‘Winner’s curse bias’ [48, 49]. We acknowledge that dichotomizing the population based on their GRS may not be the most efficient method for performing factorial MR and we cannot rule out a possible unobserved interaction between IGF-1 and BMI on knee OA risk. Recently, an alternative method was proposed for greater power in factorial MR analyses, using the complete set of instruments and their interactions [50]. The overall UK Biobank population is predominantly white British, with a higher prevalence of home-owners and non-smokers, a lower BMI and fewer self-reported health concerns than the general population [51], and MR analyses were restricted to those of white European ancestry, limiting generalizability. ‘Survivor bias’ may explain associations observed; if higher IGF-1 levels are related to a lower mortality risk, those with higher IGF-1 levels will be surviving long enough to develop chronic diseases such as OA. However, IGF-1 levels appear independent of all-cause mortality [52]. The UK Biobank population is limited by latent population structure even after restricting to white Europeans and adjusting for PCs [53], which may confound the relationship between IGF-1 and hospital-diagnosed hip OA. The discrepancy between observational and MR analyses most likely reflects unmeasured confounding, highlighting the utility of MR.

We identified robust evidence that higher concentrations of serum IGF-1 are a causal risk factor for hip OA in a very large UK population, with some evidence for a causal role in knee OA, and no evidence for an association with hand OA. Our MVMR analyses suggest that this causal role is independent of BMI, consistent with our observational analyses for hip, but not knee, OA. Further study is justified to determine the mechanism underlying this relationship.

Acknowledgements

This research has been conducted using the UK Biobank Resource under Application Number 17295. A.H. is funded by the Wellcome Trust (grant ref. 20378/Z/16/Z). C.L.G. was funded by Versus Arthritis (grant ref. 20000). Support for the IGF-1 GWAS meta-analysis (A.T., R.C.K.) was provided by the National Institute of Aging (grant ref. 1R01AG031890) and the National Heart, Lung and Blood Institute (grant ref. R01HL075516, 2R01HL105756). A.H., E.S., L.P., J.H.T. and C.L.G. work in, or are affiliated with, a University of Bristol and MRC funded unit (MC_UU_00011/1).

Data availability

UK Biobank data is available through a procedure described at https://www.ukbiobank.ac.uk/principles-of-access/. Hip and knee OA GWAS summary statistics are publicly available at https://www.ebi.ac.uk/gwas/.

Funding: No specific funding was received from any funding bodies in the public, commercial or not-for-profit sectors to carry out the work described in this manuscript.

Disclosure statement: The authors have declared no conflicts of interest.

Supplementary data

Supplementary data are available at Rheumatology online.

References

1 Cross M, Smith E, Hoy D et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 2014;73: 1323–30.
2. Chen A, Gupte C, Akhtar K, Smith P, Cobb J. The global economic cost of osteoarthritis: how the UK compares. Arthritis 2012;2012:1–6.

3. Laron Z. Insulin-like growth factor 1 (IGF-1): a growth hormone. 2001;54:311–6.

4. Nilsson A, Isgaard J, Lindahl A et al. Regulation by growth hormone of number of chondrocytes containing IGF-1 in rat growth plate. Science 1986;233:571–4.

5. McQuillan DJ, Handley CJ, Campbell MA et al. Stimulation of proteoglycan biosynthesis by serum and insulin-like growth factor-I in cultured bovine articular cartilage. Biochem J 1986;240:423–30.

6. Zhang M, Zhou Q, Liang QQ et al. IGF-1 regulation of type II collagen and MMP-13 expression in rat endplate chondrocytes via distinct signaling pathways. Osteoarthritis Cartilage 2009;17:100–6.

7. Claessen KM, Ramautar SR, Pereira AM et al. Relationship between insulin-like growth factor-1 and radiographic disease in patients with primary osteoarthritis: a systematic review. Osteoarthritis Cartilage 2012;20:79–86.

8. Lloyd ME, Hart DJ, Nandra D et al. Relation between insulin-like growth factor-I concentrations, osteoarthritis, bone density, and fractures in the general population: the Chingford study. Ann Rheum Dis 1996;55:870–4.

9. Meulenbelt I, Bijkerk C, Miedema HS et al. A genetic association study of the IGF-1 gene and radiological osteoarthritis in a population-based cohort study (the Rotterdam Study). Ann Rheum Dis 1998;57:371–4.

10. Zhai G, Rivadeneira F, Houwing-Duistermaat JJ et al. Insulin-like growth factor I gene promoter polymorphism, collagen type II alpha1 (COL2A1) gene, and the prevalence of radiographic osteoarthritis: the Rotterdam Study. Ann Rheum Dis 2004;63:544–8.

11. Zengini E, Hatzikotoulas K, Tachmaziou I et al. Genome-wide analyses using UK Biobank data provide insights into the genetic architecture of osteoarthritis. Nat Genet 2018;50:549–58.

12. Faupel-Badger JM, Berrigan D, Ballard-Barbash R, Potischman N. Anthropometric correlates of insulin-like growth factor 1 (IGF-1) and IGFBP-3 levels by race/ethnicity and gender. Ann Epidemiol 2009;19:841–9.

13. Lawlor DA, Harbord RM, Sterne JA, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med 2008;27:1133–63.

14. Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination of multivariable Mendelian randomization in the single-sample and two-sample summary data settings. Int J Epidemiol 2019;48:713–27.

15. Allen NE, Sudlow C, Peakman T, Collins R; on behalf of UK Biobank. UK biobank data: come and get it. Sci Transl Med 2014;6:224ed4.

16. Fry D, Almond R, Moffat S, Gordon M, Singh P. UK Biobank Biomarker Project: companion document to accompany serum biomarker data version 1.0. 2019. Available from: https://biobank.ndph.ox.ac.uk/showcase/docs/serum_biochemistry.pdf.

17. UK Biobank. Biomarker assay quality procedures: approaches used to minimise systematic and random errors (and the wider epidemiological implications). 2019. Available from: http://biobank.ctsu.ox.ac.uk/crystal/crystal/docs/biomarker_issues.pdf.

18. NHS Digital. Hospital Episode Statistics (HES). Available from: https://digital.nhs.uk/data-and-information/data-tools-and-services/data-services/hospital-episode-statistics (26 March 2019, date last edited).

19. Funck-Brentano T, Netherand M, Movéare-Skr tic S, Richette P, Ohlsson C. Causal factors for knee, hip and hand osteoarthritis: a Mendelian randomization study in the UK Biobank. Arthritis Rheumatol 2019;71:1634–41.

20. Tachmaziou I, Hatzikotoulas K, Southam L et al. Identification of new therapeutic targets for osteoarthritis through genome-wide analyses of UK Biobank data. Nat Genet 2019;51:230–6.

21. Bycroft C, Freeman C, Petkova D et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 2018;562:203–9.

22. Mitchell R, Hemani G, Dudding T et al. UK Biobank genetic data: MRC-IEU quality control version 2 2019. Available from: https://data.bris.ac.uk/datasets/1oaausxunp2cv8rbcy8686v/UK%20Biobank%20Genetic%20Data_MRC%20IEU%20Quality%20Control%20version%202.pdf.

23. Teumer A, Qi Q, Nethander M, Aschard H et al. Genomewide meta-analysis identifies loci associated with IGF-I and IGFBP-3 levels with impact on age-related traits. Aging Cell 2016;15:811–24.

24. Baum CF, Schaffer ME, Stillman S. IVREG2: stata module for extended instrumental variables/2SLS and GMM estimation. Statistical Software Components: Boston College Department of Economics, 2002.

25. Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for Mendelian randomization. Stat Methods Med Res 2017;26:2333–55.

26. Zheng J, Baird D, Borges MC et al. Recent developments in Mendelian randomization studies. Curr Epidemiol Rep 2017;4:330–45.

27. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol 2016;40:304–14.

28. Brion MJ, Shakhbazov K, Visscher PM. Calculating statistical power in Mendelian randomization studies. Int J Epidemiol 2013;42:1497–501.

29. Rietveld CA, Medland SE, Derlinger J et al. GWAS of 126,559 individuals identifies genetic variants associated with educational attainment. Science 2013;340:1467–71.

30. Loh P-R, Kichaev G, Gazzal S, Schoe AP, Price AL. Mixed-model association for biobank-scale datasets. Nat Genet 2018;50:906–8.

31. Mitchell R, Elsworth B, Raistrick CA et al. MRC-IEU UK Biobank GWAS Pipeline Version 2. 2019. Available from:
Mendelian randomization provides evidence for a causal effect of higher serum IGF-1 concentration

https://data.bris.ac.uk/datasets/pnoat8cx90u52ppynfkega/MRC%20IEU%20UK%20Biobank%20GWAS%20pipeline%20version%202.pdf

32 Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet 2017;13:e1007081.

33 Hemani G, Zheng J, Elsworth B et al. The MR-Base platform supports systematic causal inference across the human phenotype. eLife 2018;7:e34408.

34 Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 2015;44:512–25.

35 Locke AE, Kahali B, Berndt SI et al. Genetic studies of body mass index yield new insights for obesity biology. Nature 2015;518:197–206.

36 Vaessen N, Heutink P, Janssen JA et al. A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 2001;50:637–42.

37 Fraenkel L, Zhang Y, Trippel SB et al. Longitudinal analysis of the relationship between serum insulin-like growth factor-I and radiographic knee osteoarthritis. Osteoarthritis Cartilage 1998;6:362–7.

38 Hochberg MC, Lethbridge-Cejku M, Scott WW Jr et al. Serum levels of insulin-like growth factor-I and radiographic knee osteoarthritis. Osteoarthritis Cartilage 1994;37:1177–80.

39 Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Clin Geriatr Med 2010;26:355–69.

40 Evans DS, Callotto F, Parimi N et al. Genome-wide association and functional studies identify a role for IGFBP3 in hip osteoarthritis. Ann Rheum Dis 2015;74:1861–7.

41 Davies NM, Holmes MV D, Smith G. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ 2018;362:k601.

42 Hardcastle SA, Dieppe P, Gregson CL, Davey Smith G, Tobias JH. Osteoarthritis and bone mineral density: are strong bones bad for joints? Bonekey Rep 2015;4:624.

43 Yakar S, Wemer H, Rosen CJ. Insulin-like growth factors: actions on the skeleton. J Mol Endocrinol 2018;61:1115–37.

44 Guntur AR, Rosen CJ. IGF-1 regulation of key signaling pathways in bone. Bonekey Rep 2013;2:437.

45 Baird DA, Evans DS, Kamranu FK et al. Identification of novel loci associated with hip shape: a meta-analysis of genome-wide association studies. J Bone Miner Res 2019;34:241–51.

46 Faber BG, Baird D, Gregson CL et al. DXA-derived hip shape is related to osteoarthritis: findings from the MrOS cohort. Osteoarthritis Cartilage 2017;25:2031–8.

47 Felson DT, Lawrence RC, Dieppe PA et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med 2000;133:635–46.

48 Yengo L, Sidorenko J, Kemper KE et al. Meta-analysis of genome-wide association studies for height and body mass index in ~700000 individuals of European ancestry. Hum Mol Genet 2018;27:3641–9.

49 Haycock PC, Burgess S, Wade KH et al. Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies. Am J Clin Nutr 2016;103:965–78.

50 Rees JMB, Foley CN, Burgess S. Factorial Mendelian randomization: using genetic variants to assess interactions. Int J Epidemiol 2019; doi: 10.1093/ije/dyz161.

51 Fry A, Littlejohns TJ, Sudlow C et al. Comparison of sociodemographic and health-related characteristics of UK biobank participants with those of the general population. Am J Epidemiol 2017;186:1026–34.

52 Saydah S, Graubard B, Ballard-Barbash R, Berrigan D. Insulin-like growth factors and subsequent risk of mortality in the United States. Am J Epidemiol 2007;166:518–26.

53 Haworth S, Mitchell R, Corbin L et al. Apparent latent structure within the UK Biobank sample has implications for epidemiological analysis. Nat Commun 2019;10:333.
Mendelian randomization provides evidence for a causal effect of higher serum IGF-1 concentration